Biotech RadarJobs updated

COMPANY

ORIC Pharmaceuticals

HQ: South San Francisco, CA source · oricpharma.com ↗

Clinical Phase 3

Keywords: oncology cancer Metastatic Castration Resistant Prostate Cancer Metastatic Prostate Cancer EGFR Exon 20 Insertion Mutations NSCLC EGFR-mutated NSCLC Relapsed or Refractory Multiple Myeloma Prostatic Neoplasms ORIC-101 ORIC-114 ORIC-944 ORIC-533

Location: South San Francisco, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

$125.0MRaised (2 yrs)10Trials (company is sponsor)

Timeline

  1. Trial start Phase 3: A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) source ↗
  2. Raise Private placement: $125M (total, as published), announced May 28, 2025. Source: company release on GlobeNewswire. source ↗
  3. Trial start Phase 1: ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC source ↗
  4. Trial start Phase 1: Effect of Food on the Pharmacokinetics of ORIC-114 source ↗
  5. Trial start Phase 1: Study of ORIC-944 in Patients With Metastatic Prostate Cancer source ↗
  6. Trial start Phase 1/Phase 2: Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration source ↗
  7. Trial start Phase 1: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma source ↗
  8. Trial start Phase 1: Study of ORIC-101 in Combination With Enzalutamide source ↗
  9. Trial start Phase 1: Study of ORIC-101 in Combination With Anticancer Therapy source ↗
  10. Trial start Phase 1: Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects source ↗
  11. Trial start Phase 1: Study of ORIC-101 in Healthy Adult Subjects source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $125.0M. Last 2 years.

Clinical trials (lead sponsor) 10

RecordTitlePhaseStatusStartPrimary completion
NCT07723248A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)Phase 3RecruitingAug 3, 20262028-03 (estimated)
NCT05315700Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 AlterationPhase 1/Phase 2RecruitingMar 10, 20222026-09 (estimated)
NCT05413421Study of ORIC-944 in Patients With Metastatic Prostate CancerPhase 1RecruitingJun 1, 20222027-06 (estimated)
NCT06816992ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLCPhase 1RecruitingFeb 27, 20252026-12 (estimated)
NCT05227144Study of ORIC-533 in Relapsed or Refractory Multiple MyelomaPhase 1CompletedJan 6, 2022Mar 3, 2025 (actual)
NCT06012721Effect of Food on the Pharmacokinetics of ORIC-114Phase 1CompletedSep 11, 2023Nov 23, 2023 (actual)
NCT03928314Study of ORIC-101 in Combination With Anticancer TherapyPhase 1TerminatedMay 2, 2019Sep 22, 2022 (actual)
NCT04033328Study of ORIC-101 in Combination With EnzalutamidePhase 1TerminatedOct 28, 2019Nov 22, 2022 (actual)
NCT03835637Single and Multiple Dose Study of ORIC-101 in Adult Healthy SubjectsPhase 1CompletedMar 23, 2018Jul 4, 2018 (actual)
NCT03324555Study of ORIC-101 in Healthy Adult SubjectsPhase 1CompletedOct 19, 2017Dec 18, 2017 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback